# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- Reuters
– 23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit, including one confirmed partial response – 23ME...
23andMe Holding (NASDAQ:ME) reported quarterly losses of $(0.43) per share. The company reported quarterly sales of $64.028 mi...
Lemonaid Health will offer customers more affordable access to branded ED medication STENDRA that may be taken as early as ~15 ...
-SEC Filing
23andMe Holding Co. (NASDAQ:ME) ("23andMe"), a leading human genetics and biopharmaceutical company, today announced th...